BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45
BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.
Stocks · News reference
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Twist Bioscience Corp (TWST)
Filed: 2026-08-19 AccNo: 0001104659-26-098830 Size: 214 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven protein design campaign. The bullish momentum overshadows a critical short report published on X by activist short-seller Scorpion Capital.